Key facts
- This page summarizes DEERFIELD PARTNERS, L.P.'s Form 3 filing for Larimar Therapeutics, Inc. (LRMR).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Sep 2022, 20:30.
DEERFIELD PARTNERS, L.P. - 16 Sep 2022 Form 3 Insider Report for Larimar Therapeutics, Inc. (LRMR)
- Reporting relationship
- Director, Dir. by Deputization/10% Group, 10%+ Owner
- Issuer ticker
- LRMR
- Reported as of
- 16 Sep 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 20 Sep 2022, 20:30:58 UTC
- Next SEC filing
- 07 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Isler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
DEERFIELD PARTNERS, L.P. filed Form 3 for Larimar Therapeutics, Inc. (LRMR) on 20 Sep 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,777,777
- Date
- 16 Sep 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
SEC remarks
Jonathan Leff, a partner in Deerfield Management Company, L.P., serves as a director of the Issuer. Please see Joint Filer Information Statement attached as Exhibit 99 hereto. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.